Literature DB >> 27670376

Characterisation of the faecal microbiota in Japanese patients with paediatric-onset primary sclerosing cholangitis.

Kentaro Iwasawa1,2, Wataru Suda3,4, Tomoyuki Tsunoda5, Manari Oikawa-Kawamoto1,6, Shuichiro Umetsu1, Ayano Inui1, Tomoo Fujisawa1, Hidetoshi Morita7, Tsuyoshi Sogo1, Masahira Hattori3,8.   

Abstract

Entities:  

Keywords:  INFLAMMATORY BOWEL DISEASE; INTESTINAL MICROBIOLOGY; PAEDIATRIC LIVER DISEASE; PRIMARY SCLEROSING CHOLANGITIS; ULCERATIVE COLITIS

Mesh:

Year:  2016        PMID: 27670376      PMCID: PMC5530472          DOI: 10.1136/gutjnl-2016-312533

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


× No keyword cloud information.
Dear Sir, Primary sclerosing cholangitis (PSC) is a liver disease often associated with IBD.1 Dysbiosis of the gut microbiota is implicated in PSC aetiology in adults,2–4 but less is known about paediatric-onset PSC. We analysed the faecal microbiota of 27 Japanese patients with paediatric-onset PSC as well as 16 age-matched patients with UC and 23 healthy controls (HCs) (see online supplementary table S1) with pyrosequencing data of 16S rRNA gene V1-V2 region (accession #DRA004773). We assessed the influence of medications on the gut microbiota and found that salazosulfapyridine (SASP) treatment affected the microbiota structure with significant changes in the abundance of six major genera between the treated and untreated patients with PSC, perhaps due to its bactericidal property (see online supplementary figure S1). We thus report the analysis of 13 patients with PSC and 15 patients with UC and 23 HCs, all SASP untreated (see online supplementary table S2). Clustering analysis of the 16S reads revealed that the microbiota in the PSC and HC groups had significantly high species richness compared with the UC group, and the species richness of PSC samples was lower than that of HCs. The PSC group also exhibited an intermediate trend in the Shannon's index between the UC and HC groups (figure 1A). The unweighted UniFrac metric revealed a significant difference in the overall microbiota structure among the three groups, in which the PSC samples tended to aggregate between the HC and UC samples (figure 1B, C). Collectively, the data suggested that the patients with paediatric-onset PSC had gut microbial dysbiosis, the degree of which was less than that of the patients with UC. Dysbiosis in PSC appears to be common regardless of age and the host's genetic background.2 3
Figure 1

Comparison of the overall faecal microbiota structure among the primary sclerosing cholangitis (PSC), UC and healthy control (HC) groups. (A) Microbial richness and α-diversity in the faecal microbiota of 13 PSC and 15 UC patients without salazosulfapyridine (SASP) treatment and 23 HCs. Richness was evaluated by the observed and the Chao 1-estimated Operational Taxonomic Unit (OTU) numbers generated from clustering of 3000 16S reads per sample, and diversity is based on Shannon's index. Kruskal-Wallis test followed by Steel-Dwass test was used for multiple comparisons (*p<0.05, **p<0.01, ***p<0.001). (B) Principal coordinate analysis (PCoA) based on the unweighted UniFrac analysis of bacterial community structures of the PSC (red), UC (green), and HC (blue) groups. (C) Evaluation of dissimilarity between two groups by permutational multivariate analysis of variance (PERMANOVA). R2 indicates the coefficient of determination. Significant p values are in bold.

Comparison of the overall faecal microbiota structure among the primary sclerosing cholangitis (PSC), UC and healthy control (HC) groups. (A) Microbial richness and α-diversity in the faecal microbiota of 13 PSC and 15 UC patients without salazosulfapyridine (SASP) treatment and 23 HCs. Richness was evaluated by the observed and the Chao 1-estimated Operational Taxonomic Unit (OTU) numbers generated from clustering of 3000 16S reads per sample, and diversity is based on Shannon's index. Kruskal-Wallis test followed by Steel-Dwass test was used for multiple comparisons (*p<0.05, **p<0.01, ***p<0.001). (B) Principal coordinate analysis (PCoA) based on the unweighted UniFrac analysis of bacterial community structures of the PSC (red), UC (green), and HC (blue) groups. (C) Evaluation of dissimilarity between two groups by permutational multivariate analysis of variance (PERMANOVA). R2 indicates the coefficient of determination. Significant p values are in bold. The comparison of microbial abundance identified nine genera showing significant changes among the three groups (figure 2A). The abundance of Parabacteroides and Enterococcus was significantly decreased and increased in the PSC and UC groups compared with HCs, respectively. Over-representation of the Enterococcus genus in adult PSC was also reported.3 The other seven genera showed significant changes in abundance only between the UC and HC groups. However, the abundance of Faecalibacterium, Ruminococcus and Roseburia was significantly higher in the PSC than UC group. Since these three genera include many species producing an anti-inflammatory butyrate, there might be a different degree of inflammatory states between PSC and UC.1 At the species level, we identified 16 species showing significant changes in abundance among the three groups (figure 2B). The significant reduction of Anaerostipes hadrus, Parabacteroides distasonis and Blautia obeum was observed in both the PSC and UC groups, whereas the other seven species were significantly reduced only in the UC group. Regarding the increased species in the PSC group, the abundance of Streptococcus parasanguinis, Veillonella sp. 3_1_44, Enterococcus faecium, and Enterococcus sp. NBRC 107345 was significantly increased in the PSC compared with HCs. Of them, only S. parasanguinis showed a significant enrichment in the PSC compared with UC group. It was also reported that the Streptococcus genus tended to be more abundant in PSC than HC.3 The significant enrichment of Veillonella sp. 3_1_44 in the present PSC group is similar to that of the previous report on adult PSC.2 A concurrent proliferation of the Velillonella and Streptococcus species might involve immunomodulation mediated by symbiotic interactions between these two species in PSC.5 Overall, our data suggest that several distinct species belonging to the genus Enterococcus, Streptococcus and Veillonella are associated with the pathogenicity of paediatric-onset PSC.
Figure 2

Comparison of the microbial abundance among the primary sclerosing cholangitis (PSC), UC and healthy control (HC) groups. (A) The fold changes of PSC/HC and UC/HC of 18 dominant genera showing >0.5% mean abundance in the three groups, accounting for 90.3% of the total reads. (B) The fold changes of PSC/HC and UC/HC of 16 significant species showing >0.2% mean abundance in the three groups, accounting for 20.6% of the total reads. The fold change was calculated from dividing the mean relative abundance of each genus and species in the PSC and UC groups by that in the HCs, respectively. The mean abundance (%) in the HCs is shown in parentheses. Horizontal axis: the fold change displayed in log10. Since the abundance of Bacteroides sp. D1 in the UC group was ‘zero’, the fold change was not shown. Red and green bars indicate the fold change of PSC/HC and UC/HC, respectively. Significance was determined by the Kruskal-Wallis test followed by the Steel-Dwass test for multiple comparisons (*p<0.05, **p<0.01, ***p<0.001).

Comparison of the microbial abundance among the primary sclerosing cholangitis (PSC), UC and healthy control (HC) groups. (A) The fold changes of PSC/HC and UC/HC of 18 dominant genera showing >0.5% mean abundance in the three groups, accounting for 90.3% of the total reads. (B) The fold changes of PSC/HC and UC/HC of 16 significant species showing >0.2% mean abundance in the three groups, accounting for 20.6% of the total reads. The fold change was calculated from dividing the mean relative abundance of each genus and species in the PSC and UC groups by that in the HCs, respectively. The mean abundance (%) in the HCs is shown in parentheses. Horizontal axis: the fold change displayed in log10. Since the abundance of Bacteroides sp. D1 in the UC group was ‘zero’, the fold change was not shown. Red and green bars indicate the fold change of PSC/HC and UC/HC, respectively. Significance was determined by the Kruskal-Wallis test followed by the Steel-Dwass test for multiple comparisons (*p<0.05, **p<0.01, ***p<0.001). Further studies may confirm the PSC-associated bacteria observed here, and the influence of differences in medications as described here, disease duration, nationalities and methodologies on the gut microbiota should be considered.
  5 in total

1.  Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis.

Authors:  Malte Christoph Rühlemann; Femke-Anouska Heinsen; Roman Zenouzi; Wolfgang Lieb; Andre Franke; Christoph Schramm
Journal:  Gut       Date:  2016-05-23       Impact factor: 23.059

Review 2.  Primary sclerosing cholangitis.

Authors:  Gideon M Hirschfield; Tom H Karlsen; Keith D Lindor; David H Adams
Journal:  Lancet       Date:  2013-06-28       Impact factor: 79.321

3.  The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls.

Authors:  Martin Kummen; Kristian Holm; Jarl Andreas Anmarkrud; Ståle Nygård; Mette Vesterhus; Marte L Høivik; Marius Trøseid; Hanns-Ulrich Marschall; Erik Schrumpf; Bjørn Moum; Helge Røsjø; Pål Aukrust; Tom H Karlsen; Johannes R Hov
Journal:  Gut       Date:  2016-02-17       Impact factor: 23.059

4.  Immunomodulatory properties of Streptococcus and Veillonella isolates from the human small intestine microbiota.

Authors:  Bartholomeus van den Bogert; Marjolein Meijerink; Erwin G Zoetendal; Jerry M Wells; Michiel Kleerebezem
Journal:  PLoS One       Date:  2014-12-05       Impact factor: 3.240

5.  Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD.

Authors:  João Sabino; Sara Vieira-Silva; Kathleen Machiels; Marie Joossens; Gwen Falony; Vera Ballet; Marc Ferrante; Gert Van Assche; Schalk Van der Merwe; Severine Vermeire; Jeroen Raes
Journal:  Gut       Date:  2016-05-20       Impact factor: 23.059

  5 in total
  20 in total

Review 1.  Functional Microbiomics in Liver Transplantation: Identifying Novel Targets for Improving Allograft Outcomes.

Authors:  Michael Kriss; Elizabeth C Verna; Hugo R Rosen; Catherine A Lozupone
Journal:  Transplantation       Date:  2019-04       Impact factor: 4.939

2.  The "gut microbiota" hypothesis in primary sclerosing cholangitis.

Authors:  Valerio Pontecorvi; Marco Carbone; Pietro Invernizzi
Journal:  Ann Transl Med       Date:  2016-12

3.  Intestinal barrier regulates immune responses in the liver via IL-10-producing macrophages.

Authors:  Nobuhito Taniki; Nobuhiro Nakamoto; Po-Sung Chu; Yohei Mikami; Takeru Amiya; Toshiaki Teratani; Takahiro Suzuki; Tomoya Tsukimi; Shinji Fukuda; Akihiro Yamaguchi; Shunsuke Shiba; Rei Miyake; Tadashi Katayama; Hirotoshi Ebinuma; Takanori Kanai
Journal:  JCI Insight       Date:  2018-06-21

4.  Gut microbiome in liver pathophysiology and cholestatic liver disease.

Authors:  Shengmin Yan; Xiao-Ming Yin
Journal:  Liver Res       Date:  2021-08-08

Review 5.  The intestinal and biliary microbiome in autoimmune liver disease-current evidence and concepts.

Authors:  Timur Liwinski; Melina Heinemann; Christoph Schramm
Journal:  Semin Immunopathol       Date:  2022-05-10       Impact factor: 11.759

6.  The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease.

Authors:  J Torres; C Palmela; H Brito; X Bao; H Ruiqi; P Moura-Santos; J Pereira da Silva; A Oliveira; C Vieira; K Perez; S H Itzkowitz; J F Colombel; L Humbert; D Rainteau; M Cravo; C M Rodrigues; J Hu
Journal:  United European Gastroenterol J       Date:  2017-05-05       Impact factor: 4.623

Review 7.  Gut microbiome, liver immunology, and liver diseases.

Authors:  Rui Wang; Ruqi Tang; Bo Li; Xiong Ma; Bernd Schnabl; Herbert Tilg
Journal:  Cell Mol Immunol       Date:  2020-12-14       Impact factor: 11.530

8.  Intestinal Microbiome-Macrophage Crosstalk Contributes to Cholestatic Liver Disease by Promoting Intestinal Permeability in Mice.

Authors:  Anna Isaacs-Ten; Marta Echeandia; Mar Moreno-Gonzalez; Arlaine Brion; Andrew Goldson; Mark Philo; Angela M Patterson; Aimee Parker; Mikel Galduroz; David Baker; Simon M Rushbrook; Falk Hildebrand; Naiara Beraza
Journal:  Hepatology       Date:  2020-12       Impact factor: 17.298

9.  Altered Gut Microbial Metabolism of Essential Nutrients in Primary Sclerosing Cholangitis.

Authors:  Martin Kummen; Louise B Thingholm; Malte C Rühlemann; Kristian Holm; Simen H Hansen; Lucas Moitinho-Silva; Timur Liwinski; Roman Zenouzi; Christopher Storm-Larsen; Øyvind Midttun; Adrian McCann; Per M Ueland; Marte L Høivik; Mette Vesterhus; Marius Trøseid; Matthias Laudes; Wolfgang Lieb; Tom H Karlsen; Corinna Bang; Christoph Schramm; Andre Franke; Johannes R Hov
Journal:  Gastroenterology       Date:  2020-12-31       Impact factor: 22.682

10.  Multi-Omics Analysis Reveals Disturbance of Nanosecond Pulsed Electric Field in the Serum Metabolic Spectrum and Gut Microbiota.

Authors:  Yeping Dong; Jiahua Lu; Ting Wang; Zhiliang Huang; Xinhua Chen; Zhigang Ren; Liangjie Hong; Haiyu Wang; Dezhi Yang; Haiyang Xie; Wu Zhang
Journal:  Front Microbiol       Date:  2021-07-02       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.